Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses FHTX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named FHTX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Adrian Gottschalk | $638,000 | $0 | $0 | $1,334,037 | $385,990 | $0 | $3,000 | $2,361,027 |
| President and Chief Executive Officer | ||||||||
| Steven Bellon | 505,000 | 0 | 0 | 469,255 | 222,200 | 0 | 3,000 | 1,199,455 |
| Chief Scientific Officer | ||||||||
| Alfonso Quintas-Cardama | 494,000 | 0 | 0 | 419,605 | 217,360 | 0 | 3,000 | 1,133,965 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Adrian Gottschalk | $2,361,027 | $1,559,562 | — | +801,465 |
| Steven Bellon | 1,199,455 | 902,212 | — | +297,243 |
| Alfonso Quintas-Cardama | 1,133,965 | 769,489 | — | +364,476 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Stuart Duty | Director | 2026-06-24 | A | 28,000 | $4 | $114,240 | Derivative, Class A Common | Form 4 ↗ |
| Neil Gallagher | Director | 2026-06-24 | A | 28,000 | 4 | 114,240 | Derivative, Class A Common | Form 4 ↗ |
| Thomas J. Lynch Jr. | Director | 2026-06-24 | A | 28,000 | 4 | 114,240 | Derivative, Class A Common | Form 4 ↗ |
| Scott Biller | Director | 2026-06-24 | A | 28,000 | 4 | 114,240 | Derivative, Class A Common | Form 4 ↗ |
| Michael Mendelsohn | Director | 2026-06-24 | A | 28,000 | 4 | 114,240 | Derivative, Class A Common | Form 4 ↗ |
| Ian F. Smith | Director | 2026-06-24 | A | 28,000 | 4 | 114,240 | Derivative, Class A Common | Form 4 ↗ |
| Simba Gill | Director | 2026-06-24 | A | 28,000 | 4 | 114,240 | Derivative, Class A Common | Form 4 ↗ |
| B. Lynne Parshall | Director | 2026-06-24 | A | 28,000 | 4 | 114,240 | Derivative, Class A Common | Form 4 ↗ |
| Douglas G. Cole | Director | 2026-06-24 | A | 28,000 | 4 | 114,240 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Steven Bellon | Option | — | — | — | — | — | $469,255 |
| Adrian Gottschalk | Option | — | — | — | — | — | 1,334,037 |
| Alfonso Quintas-Cardama | Option | — | — | — | — | — | 419,605 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Steven Bellon | $0 | $0 | $469,255 | 0.0% |
| Adrian Gottschalk | 0 | 0 | 1,334,037 | 0.0% |
| Alfonso Quintas-Cardama | 0 | 0 | 419,605 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Steven Bellon | Option | 61,875 | 3.06 | — |
| Steven Bellon | Option | 9,375 | 14.87 | — |
| Steven Bellon | Option | 140,000 | 4.37 | — |
| Adrian Gottschalk | Option | 87,500 | 8.38 | — |
| Alfonso Quintas-Cardama | Option | 119,000 | 7.57 | — |
| Adrian Gottschalk | Option | 400,000 | 4.37 | — |
| Alfonso Quintas-Cardama | Option | 125,000 | 4.37 | — |
| Alfonso Quintas-Cardama | Option | 33,750 | 3.06 | — |
| Adrian Gottschalk | Option | 27,500 | 14.87 | — |
| Steven Bellon | Option | 31,250 | 8.38 | — |
| Adrian Gottschalk | Option | 168,750 | 3.06 | — |
Our executive compensation philosophy is designed to aid in attracting and retaining a high caliber workforce capable of delivering results at the leading edge of science, medicine, and business.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pay Governance, LLC |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-24 | 45,637,005 | 468,947 | 5,500 | 98.98% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-24 | 98.98%a |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the results of the vote on Proposal 3.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Stuart DutyIndependent · Audit · Newly elected | $31,667 | $0 | $163,002 | — | $0 | $194,669 |
| Neil J. Gallagher, M.D., Ph.DIndependent · Science · Newly elected | 30,000 | 0 | 163,002 | — | 0 | 193,002 |
| Douglas G. Cole, M.DIndependent · Board Chair · Compensation · Nominating/Governance (Chair) | 85,351 | 0 | 91,970 | — | 0 | 177,321 |
| B. Lynne ParshallIndependent · Audit (Chair) · Nominating/Governance | 59,784 | 0 | 91,970 | — | 0 | 151,754 |
| Balkrishan (Simba) Gill, Ph.DIndependent · Audit · Compensation (Chair) | 59,067 | 0 | 91,970 | — | 0 | 151,037 |
| Michael Mendelsohn, M.DIndependent · Compensation · Science (Chair) | 55,351 | 0 | 91,970 | — | 0 | 147,321 |
| Thomas J. Lynch Jr., M.DIndependent · Nominating/Governance · Science | 48,117 | 0 | 91,970 | — | 0 | 140,087 |
| Scott Biller, Ph.DIndependent · Science | 44,784 | 0 | 91,970 | — | 0 | 136,754 |
| Ian F. SmithIndependent · Compensation | 40,000 | 0 | 91,970 | — | 0 | 131,970 |
| Adrian GottschalkEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 6,000 / 10,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $454,121 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $454,121 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Foghorn Therapeutics | 2025 | Adrian Gottschalk | $638,000 | $0 | $1,334,037 | $385,990 | $2,361,027 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Adrian Gottschalk | DEF 14A | 2026-04-30 | 0001193125-26-193928 | Section “Summary Compensation Table”. As printed: 2,361,027. Filing ↗machine: r2 · c34 · span 245360–245369 |
| 2 | Section 01, Steven Bellon | DEF 14A | 2026-04-30 | 0001193125-26-193928 | Section “Summary Compensation Table”. As printed: 1,199,455. Filing ↗machine: r5 · c34 · span 250429–250438 |
| 3 | Section 01, Alfonso Quintas-Cardama | DEF 14A | 2026-04-30 | 0001193125-26-193928 | Section “Summary Compensation Table”. As printed: 1,133,965. Filing ↗machine: t93 · r8 · c34 · span 255495–255504 |
| 4 | Section 03, Steven Bellon Option | DEF 14A | 2026-04-30 | 0001193125-26-193928 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t93 · r5 · c19 · span 249546–249553 |
| 5 | Section 03, Adrian Gottschalk Option | DEF 14A | 2026-04-30 | 0001193125-26-193928 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t93 · r2 · c19 · span 244475–244484 |
| 6 | Section 03, Alfonso Quintas-Cardama Option | DEF 14A | 2026-04-30 | 0001193125-26-193928 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 7 | Section 07, pay ratio | 10-K | 2026-03-11 | 0001628280-26-016814 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 8 | Section 08, Stuart Duty | DEF 14A | 2026-04-30 | 0001193125-26-193928 | Section “Director Compensation”. As printed: 194,669. Filing ↗machine: t119 · r4 · c14 · span 349040–349047 |
| 9 | Section 08, Neil J. Gallagher, M.D., Ph.D | DEF 14A | 2026-04-30 | 0001193125-26-193928 | Section “Director Compensation”. As printed: 193,002. Filing ↗machine: t119 · r5 · c14 · span 350205–350212 |
| 10 | Section 08, Douglas G. Cole, M.D | DEF 14A | 2026-04-30 | 0001193125-26-193928 | Section “Director Compensation”. As printed: 177,321. Filing ↗machine: t119 · r2 · c14 · span 346710–346717 |
| 11 | Section 08, B. Lynne Parshall | DEF 14A | 2026-04-30 | 0001193125-26-193928 | Section “Director Compensation”. As printed: 151,754. Filing ↗machine: t119 · r9 · c14 · span 354879–354886 |
| 12 | Section 08, Balkrishan (Simba) Gill, Ph.D | DEF 14A | 2026-04-30 | 0001193125-26-193928 | Section “Director Compensation”. As printed: 151,037. Filing ↗machine: t119 · r6 · c14 · span 351384–351391 |
| 13 | Section 08, Michael Mendelsohn, M.D | DEF 14A | 2026-04-30 | 0001193125-26-193928 | Section “Director Compensation”. As printed: 147,321. Filing ↗machine: t119 · r8 · c14 · span 353725–353732 |
| 14 | Section 08, Thomas J. Lynch Jr., M.D | DEF 14A | 2026-04-30 | 0001193125-26-193928 | Section “Director Compensation”. As printed: 140,087. Filing ↗machine: t119 · r7 · c14 · span 352539–352546 |
| 15 | Section 08, Scott Biller, Ph.D | DEF 14A | 2026-04-30 | 0001193125-26-193928 | Section “Director Compensation”. As printed: 136,754. Filing ↗machine: t119 · r3 · c14 · span 347866–347873 |
| 16 | Section 08, Ian F. Smith | DEF 14A | 2026-04-30 | 0001193125-26-193928 | Section “Director Compensation”. As printed: 131,970. Filing ↗machine: t119 · r10 · c14 · span 355936–355943 |
| 17 | Section 08, Adrian Gottschalk | DEF 14A | 2026-04-30 | 0001193125-26-193928 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 18 | Section 02, Stuart Duty 2026-06-24 | Form 4 | 2026-06-25 | 0001970274-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Neil Gallagher 2026-06-24 | Form 4 | 2026-06-25 | 0001972849-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Thomas J. Lynch Jr. 2026-06-24 | Form 4 | 2026-06-25 | 0001474056-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Scott Biller 2026-06-24 | Form 4 | 2026-06-25 | 0001581956-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Michael Mendelsohn 2026-06-24 | Form 4 | 2026-06-25 | 0001591109-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Ian F. Smith 2026-06-24 | Form 4 | 2026-06-25 | 0001197032-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Simba Gill 2026-06-24 | Form 4 | 2026-06-25 | 0001180763-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, B. Lynne Parshall 2026-06-24 | Form 4 | 2026-06-25 | 0001073385-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Douglas G. Cole 2026-06-24 | Form 4 | 2026-06-25 | 0001486373-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 06, 2026 vote | Form 8-K | 2026-06-24 | 0001628280-26-045154 | Item 5.07 · say-on-pay result. As reported: 98.98% (votes for as printed: 45,637,005). Filing ↗ |
| 28 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 29 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 30 | Section 09b board cost (computed) | Computed | — | computed | Cash 454,121 + equity 0 + all other 0 = 454,121, summed across the director compensation table rows.machine: formula: Σ = 454,121 |
| 31 | Foghorn Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-193928 | CEO total compensation as printed in Foghorn Therapeutics's own proxy. As printed: 2,361,027. Filing ↗machine: r2 · c34 · span 245360–245369 |